Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- September30 2004
- Volume 11
- Issue 18
Major Medical Issue
Advertisement
"As I have traveled our country, I have met too many good doctors?forced outof practice because of the high cost of lawsuits. To make health care more affordableand accessible, we must pass medical liability reform now. And in all we doto improve health care in America, we will make sure that health decisions aremade by doctors and patients, not by bureaucrats in Washington, DC."
—President George W. Bush
Republican Party Nomination Speech, Sept. 2004
Articles in this issue
about 18 years ago
Discover the Value of Staying Involvedabout 18 years ago
Has Diversification Been Resurrected?about 18 years ago
Retire the Jersey of Your Aging Stocksabout 18 years ago
Climb the Ladder of Bond Investingabout 18 years ago
Consider Your Options in Foreign Stocksabout 18 years ago
Shrink Away from Your Big Mutual Fundsabout 18 years ago
Click on the Best Online Stockbrokerabout 18 years ago
Doc's Stocks Contest #12 Current Standingsabout 18 years ago
Close-Up: Business Entitiesabout 18 years ago
Grasp the Super IRA's Asset ProtectionAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5